ARDX:NSD-Ardelyx, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 7.84

Change

+0.64 (+8.89)%

Market Cap

USD 0.71B

Volume

2.55M

Average Target Price

USD 14.00 (+78.57%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of patients with hyperkalemia; and RDX020, a small molecule program for the treatment of metabolic acidosis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Fremont, California.

Company Website : http://www.ardelyx.com

Address : 34175 Ardenwood Boulevard, Fremont, CA, United States, 94555

Employees : 129

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.95

52 Week High : 8.35

Short Ratio : 6.92

52 Week Low : 4.96

Shorted Shares : 8,858,369

200 Day Moving Average : 6.42

Shorted Shares Previous Month : 5,736,878

50 Day Moving Average : 6.81

Shares Held By Insiders : 13.17%

Short Percentage : 9.00%

Shares Held by Institutions : 80.64%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-14 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+10.32 (+6.89%)

 USD59.96B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

+1.19 (+0.55%)

 USD55.89B 20.99 15.27
REGN Regeneron Pharmaceuticals, Inc

+4.12 (+0.86%)

 USD51.11B 15.63 12.19
ALXN Alexion Pharmaceuticals, Inc

+1.56 (+1.01%)

 USD33.80B 56.52 33.71
BNTX BioNTech SE

+2.96 (+2.28%)

 USD31.31B -99,999.99 N/A
BGNE BeiGene, Ltd

+0.34 (+0.11%)

 USD28.62B N/A N/A
SGEN Seagen Inc

+3.31 (+2.35%)

 USD25.54B 41.81 34.88
RPRX Royalty Pharma plc

+0.69 (+1.67%)

 USD25.15B 22.60 15.33
GMAB Genmab A/S

+0.02 (+0.06%)

 USD22.68B 26.59 3.21
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing ARDX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 21.17% 73% C 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 21.17% 73% C 69% D+
Trailing 12 Months  
Capital Gain 17.19% 43% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.19% 42% F 22% F
Trailing 5 Years  
Capital Gain -4.74% 53% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.74% 53% F 23% F
Average Annual (5 Year Horizon)  
Capital Gain 10.82% 48% F 59% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.82% 47% F 57% F
Risk Return Profile  
Volatility (Standard Deviation) 86.59% 32% F 17% F
Risk Adjusted Return 12.49% 42% F 36% F
Market Capitalization 0.71B 64% D 57% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 5.82 41% F 30% F
Price / Cash Flow Ratio -8.72 53% F 74% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -60.31% 51% F 20% F
Return on Invested Capital -43.90% 55% F 19% F
Return on Assets -24.60% 53% F 16% F
Debt to Equity Ratio 36.97% 30% F 48% F
Technical Ratios  
Short Ratio 6.92 25% F 11% F
Short Percent 10.81% 29% F 19% F
Beta 1.95 24% F 16% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector